HC Wainwright Predicts Weaker Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Equities researchers at HC Wainwright lowered their Q2 2025 EPS estimates for Legend Biotech in a research note issued on Wednesday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of $0.24 per share for the quarter, down from their prior estimate of $0.28. HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.12 EPS.

Legend Biotech (NASDAQ:LEGN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.22. Legend Biotech had a negative return on equity of 29.22% and a negative net margin of 66.92%. The business had revenue of $160.20 million for the quarter, compared to analysts’ expectations of $143.91 million. During the same period in the prior year, the business posted ($0.17) earnings per share. The firm’s revenue was up 66.9% on a year-over-year basis.

Several other brokerages have also issued reports on LEGN. Scotiabank boosted their price target on Legend Biotech from $70.00 to $76.00 and gave the company a “sector outperform” rating in a research note on Monday, August 12th. Royal Bank of Canada restated an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a report on Tuesday, October 29th. Finally, Redburn Atlantic started coverage on Legend Biotech in a research note on Tuesday, October 8th. They issued a “buy” rating and a $86.00 price objective for the company. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $81.46.

Legend Biotech Trading Up 1.4 %

NASDAQ:LEGN opened at $39.89 on Thursday. Legend Biotech has a 52 week low of $38.60 and a 52 week high of $70.13. The firm’s fifty day moving average is $46.49 and its 200-day moving average is $48.34. The firm has a market cap of $7.27 billion, a P/E ratio of -41.42 and a beta of 0.11. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.78 and a current ratio of 4.84.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. FMR LLC raised its stake in Legend Biotech by 4.0% in the third quarter. FMR LLC now owns 18,330,219 shares of the company’s stock valued at $893,232,000 after purchasing an additional 708,620 shares in the last quarter. RA Capital Management L.P. increased its holdings in shares of Legend Biotech by 9.5% in the 1st quarter. RA Capital Management L.P. now owns 6,861,097 shares of the company’s stock worth $384,839,000 after buying an additional 596,390 shares during the last quarter. Westfield Capital Management Co. LP raised its position in shares of Legend Biotech by 26.1% during the 1st quarter. Westfield Capital Management Co. LP now owns 2,239,774 shares of the company’s stock valued at $125,629,000 after buying an additional 463,527 shares in the last quarter. Capital International Investors lifted its holdings in shares of Legend Biotech by 19.5% during the 1st quarter. Capital International Investors now owns 2,181,074 shares of the company’s stock worth $122,336,000 after acquiring an additional 356,387 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Legend Biotech by 16.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,275,158 shares of the company’s stock worth $110,868,000 after acquiring an additional 314,449 shares in the last quarter. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).